Fed. Circ. Rules Mylan Doesn't Infringe Angiomax Patents
The Federal Circuit ruled Thursday that Mylan Inc.'s planned generic version of the blood-thinner Angiomax does not infringe two patents owned by The Medicines Co., partly reversing a lower court's decision....To view the full article, register now.
Already a subscriber? Click here to view full article